Skip Navigation
 

Funding


RCDC

Project Listing by Category


Back to Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) Click the column headings to sort project listings.
  Help
CategoryFYFunding ICProject NumberSub Project #Project TitlePI NameOrg NameState / CountryAmount
Neurofibromatosis 2016 NCI 1R35CA197709-01 New Ways of Targeting K-Ras MCCORMICK, FRANK UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $932,874
Neurofibromatosis 2016 NINDS 4R01NS077952-04 Mechanisms of cell contact inhibition and their dysregulation in cancer. KISSIL, JOSEPH SCRIPPS FLORIDA FL $420,000
Neurofibromatosis 2016 NCI 5R01CA142928-07 Targeting the Kinome in Neurofibromatosis type 1 CHERNOFF, JONATHAN RESEARCH INST OF FOX CHASE CAN CTR PA $423,938
Neurofibromatosis 2016 NIDCD 4R01DC012593-04 Safe, Rapid Access to the Internal Auditory Canal for Acoustic Neuroma WEBSTER, ROBERT VANDERBILT UNIVERSITY TN $369,511
Neurofibromatosis 2016 NCI 4R37CA072614-20 Translational Investigation of KRas & NF1 in Myeloid Leukemia SHANNON, KEVIN UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $304,773
Neurofibromatosis 2016 NINDS 5R01NS086938-03 Function & regulation of Hippo pathway effectors YAP/TAZ during brain development CAO, XINWEI ST. JUDE CHILDREN'S RESEARCH HOSPITAL TN $382,813
Neurofibromatosis 2016 NCI 1R01CA191222-01A1 Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma GIANCOTTI, FILIPPO SLOAN-KETTERING INST CAN RESEARCH NY $525,425
Neurofibromatosis 2016 NCI 2R01CA072597-17A1 Oncogenic Events in Thyroid Neoplasia FAGIN, JAMES SLOAN-KETTERING INST CAN RESEARCH NY $428,500
Neurofibromatosis 2016 NCI 2R01CA111754-11A1 Elucidating the Regulation and Function of the NF1 tumor suppressor CICHOWSKI, KAREN BRIGHAM AND WOMEN'S HOSPITAL MA $316,635
Neurofibromatosis 2016 NINDS 5R01NS091037-02 Brain Dysfunction in Neurofibromatosis RATNER, NANCY CINCINNATI CHILDRENS HOSP MED CTR OH $309,792
Neurofibromatosis 2016 NCI 1U01CA202943-01 Developing a translational pipeline for NF1-mutant malignancies CICHOWSKI, KAREN BRIGHAM AND WOMEN'S HOSPITAL MA $578,917
Neurofibromatosis 2016 NCI 4R01CA166593-05 The Roles of Tumor Microenvironment in Neurofibroma Development and Therapeutics LE, LU UT SOUTHWESTERN MEDICAL CENTER TX $329,925
Neurofibromatosis 2016 NCI 5R01CA195692-02 Leveraging Genetically-Engineered Mice to Optimize Pediatric Glioma Management GUTMANN, DAVID WASHINGTON UNIVERSITY MO $564,104
Neurofibromatosis 2016 NINDS 5R37NS083580-03 Ras Proteins in Nerve Tumorigensis RATNER, NANCY CINCINNATI CHILDRENS HOSP MED CTR OH $390,000
Neurofibromatosis 2016 NCATS 1R13CA203289-01 Developing Endpoints to Facilitate Clinical Trials in Rare Diseases PLOTKIN, SCOTT MASSACHUSETTS GENERAL HOSPITAL MA $6,000
Neurofibromatosis 2016 NCI 1R13CA203289-01 Developing Endpoints to Facilitate Clinical Trials in Rare Diseases PLOTKIN, SCOTT MASSACHUSETTS GENERAL HOSPITAL MA $3,993
Neurofibromatosis 2016 NIDCD 5F30DC014197-03 Genetic Disruption of PAK prevents NF2-deficient schwannomas and hearing loss GEHLHAUSEN, JEFF INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS IN $48,576
Neurofibromatosis 2016 NCI 4R01CA164295-05 Exploration of Activity of RAD001 in vivo in Vestibular Schwannomas and Meningiom KARAJANNIS, MATTHIAS NEW YORK UNIVERSITY SCHOOL OF MEDICINE NY $1
Neurofibromatosis 2016 NINDS 5R21NS088013-02 Translation of AAV P0 ICE schwannoma gene therapy to clinical Trials BRENNER, GARY MASSACHUSETTS GENERAL HOSPITAL MA $415,109
Neurofibromatosis 2016 NCI 4R01CA153354-05 Study of Anti-Survival signals in NF1 CHEN, CHANGYAN NORTHEASTERN UNIVERSITY MA $322,663
Neurofibromatosis 2016 NINDS 5R01NS086219-03 Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and Maintenance LARGAESPADA, DAVID UNIVERSITY OF MINNESOTA MN $486,944
Neurofibromatosis 2016 NINDS 1F30NS096796-01 Cytokine signaling in neurofibroma development FLETCHER, JONATHAN CINCINNATI CHILDRENS HOSP MED CTR OH $40,176
Neurofibromatosis 2016 NCI 4K08CA160443-05 Axl receptor signaling in MPNST; potential node for therapy TORRES, KEILA UNIVERSITY OF TX MD ANDERSON CAN CTR TX $170,618
Neurofibromatosis 2016 NINDS 4R01NS081146-05 Mechanisms of Caspase-1 Mediated Schwannoma Regression BRENNER, GARY MASSACHUSETTS GENERAL HOSPITAL MA $363,790
Neurofibromatosis 2016 NCI 4U54CA168512-05 7063 Identification of therapeutic windows for NF1-related malignant peripheral nerve ZHU, YUAN UNIVERSITY OF MICHIGAN MI $196,423
Neurofibromatosis 2016 NCI 5U54CA196519-02 7036 Core A: Omics Core JOHNSON, GARY UNIV OF NORTH CAROLINA CHAPEL HILL NC $379,518
Neurofibromatosis 2016 NCI 5U54CA196519-02 7037 Core B: Biospecimen/Pathology Core FOROUD, TATIANA INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS IN $110,721
Neurofibromatosis 2016 NCI 5U54CA196519-02 7038 Core C: Administrative Core CLAPP, DAVID INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS IN $31,924
Neurofibromatosis 2016 NCI 5U54CA196519-02 7039 Project 1: Molecular and Genetic Features Across Mouse and Human Plexiform Neurofibromas to Inform Clinical Trials CLAPP, DAVID INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS IN $121,754
Neurofibromatosis 2016 NCI 5U54CA196519-02 7040 Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors SKAPEK, STEPHEN UT SOUTHWESTERN MEDICAL CENTER TX $434,302
Neurofibromatosis 2016 NCI 5U54CA196519-02 7041 Project 3: Efficacy of MEK Inhibition in Juvenile Myelomonocytic Leukemia SHANNON, KEVIN UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $408,012
Neurofibromatosis 2016 NCI 5U54CA196519-02 7042 Project 4: Secondary Cancers Among NF1 Cancer Survivors NAKAMURA, JEAN UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $492,187
Neurofibromatosis 2016 NCI 5U54CA196519-02 7043 Developmental Research Program SHANNON, KEVIN UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $103,346
Neurofibromatosis 2016 NCI 5U54CA196519-02 7044 Career Development Program SHANNON, KEVIN UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $80,236
Neurofibromatosis 2016 NINDS 5R01NS095411-02 Targeting Tumors with NF1 Loss SANCHEZ, YOLANDA DARTMOUTH COLLEGE NH $547,736
Neurofibromatosis 2016 NINDS 1R01NS097233-01 miR-155 and RUNX function in neurofibroma tumorigenesis and therapy WU, JIANQIANG CINCINNATI CHILDRENS HOSP MED CTR OH $341,250
Neurofibromatosis 2016 NCI 1R01CA214146-01A1 DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA GUTMANN, DAVID WASHINGTON UNIVERSITY MO $348,844
Neurofibromatosis 2016 NCI 1R21CA208723-01 (PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors BETTEGOWDA, CHETAN JOHNS HOPKINS UNIVERSITY MD $212,824
Neurofibromatosis 2016 NCI 1R01CA201130-01A1 Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma RAMESH, VIJAYA MASSACHUSETTS GENERAL HOSPITAL MA $400,389
Neurofibromatosis 2016 NICHD 1R01HD089474-01 Neurobiology and Treatment of Reading Disability in NF1 CUTTING, LAURIE VANDERBILT UNIVERSITY TN $634,016
Neurofibromatosis 2016 NCATS 2R13NS084619-04 Children's Tumor Foundation 2016 Neurofibromatosis (NF) Conference FISHER, MICHAEL CHILDREN'S TUMOR FOUNDATION NY $10,000
Neurofibromatosis 2016 NINDS 2R13NS084619-04 Children's Tumor Foundation 2016 Neurofibromatosis (NF) Conference FISHER, MICHAEL CHILDREN'S TUMOR FOUNDATION NY $10,000
Neurofibromatosis 2016 NIDCD 1R01DC015824-01 Mechanisms of sensorineural hearing loss: secreted factors STANKOVIC, KONSTANTINA MASSACHUSETTS EYE AND EAR INFIRMARY MA $424,375
Neurofibromatosis 2016 NINDS 1R21NS096402-01A1 Functional analysis of pathogenic mutations in Neurofibromatosis Type-1 (NF1) WALKER, JAMES MASSACHUSETTS GENERAL HOSPITAL MA $263,150
Neurofibromatosis 2016 NINDS 1R37NS096359-01A1 Molecular and signaling mechanisms of peripheral nerve sheath tumorigenesis LU, QING CINCINNATI CHILDRENS HOSP MED CTR OH $529,965
Neurofibromatosis 2016 NINDS 1R43NS097090-01A1 Development and Characterization of a Swine Model of Neurofibromatosis Type 2 WATSON, ADRIENNE RECOMBINETICS, INC. MN $347,891
Neurofibromatosis 2016 NINDS 2R56NS034783-19 Function of NF2/Merlin in regulation of the Hippo/Salvador/Warts growth control pathway. Renewal FEHON, RICHARD UNIVERSITY OF CHICAGO IL $532,648
Neurofibromatosis 2016 NCI 1ZIACP010144-18 Clinical Genetic Studies of Familial and Hereditary Cancer Syndromes SAVAGE, SHARON NIH $9,672,204
Neurofibromatosis 2016 NCI 1ZIABC010801-10 Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes WIDEMANN, BRIGITTE NIH $1,005,422
Neurofibromatosis 2016 NCI 1ZIABC011470-05 Development of Natural Product Leads as Anticancer Therapeutics BEUTLER, JOHN NIH $408,562
Neurofibromatosis 2016 NCI 1ZIABC011734-01 Genomic dissection of tumor heterogeneity and progression SHERN, JOHN NIH $206,027
Neurofibromatosis 2016 NCI 1ZIASC010354-17 Clinical Development of Novel Drugs for Children with Refractory Cancers WIDEMANN, BRIGITTE NIH $670,281
Neurofibromatosis 2016 NINDS 1ZIANS003053-09 Neuro-oncology of Familial Neoplasia Syndromes YOULE, RICHARD NIH $811,713
Neurofibromatosis 2016 NINDS 1ZIANS003132-05 Neurooncology of Benign Central and Peripheral Nervous System Tumors HEISS, JOHN NIH $811,713
Neurofibromatosis 2016 NEI 1ZIAEY000388-15 Neuro-ophthalmic Mechanisms Of Disease FITZGIBBON, EDMOND NIH $259,770


  • Download Readers:
  • Download Adobe PDF Reader
  • Download Microsoft PowerPoint Viewer
  • Download Microsoft Word Viewer
  • Download Microsoft Excel Viewer